Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.

Oncology letters

Hertlein L, Rath J, Zeder-Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A, Jeschke U.
PMID: 28927080
Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18.

The present study aimed to identify differences in protein expression in cases of endometrioid endometrial cancer (EEC) with and without coexisting adenomyosis uteri (AM), and to evaluate the histopathological and prognostic distinctions. The total cohort included 22 patients in...

Cite
Hertlein L, Rath J, Zeder-Göss C, et al. Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncol Lett. 2017;14(3):3302-3308doi: 10.3892/ol.2017.6592.
Hertlein, L., Rath, J., Zeder-Göss, C., Fürst, S., Bayer, D., Trillsch, F., Mahner, S., Burges, A., & Jeschke, U. (2017). Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncology letters, 14(3), 3302-3308. https://doi.org/10.3892/ol.2017.6592
Hertlein, Linda, et al. "Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only." Oncology letters vol. 14,3 (2017): 3302-3308. doi: https://doi.org/10.3892/ol.2017.6592
Hertlein L, Rath J, Zeder-Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A, Jeschke U. Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18. PMID: 28927080; PMCID: PMC5588003.
Copy Download .nbib Format: NLM
Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology.

Cancer management and research

Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göß C, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F.
PMID: 31616183
Cancer Manag Res. 2019 Aug 14;11:7673-7684. doi: 10.2147/CMAR.S210004. eCollection 2019.

PURPOSE: This study aimed to investigate the potential prognostic impact of nuclear factor erythroid 2-related factor 2 (NRF2) and progesterone receptor A (PRA)/progesterone receptor B (PRB) in ovarian cancer patients which might be the rationale for putative new treatment...

Cite
Czogalla B, Kahaly M, Mayr D, et al. Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. Cancer Manag Res. 2019;11:7673-7684doi: 10.2147/CMAR.S210004.
Czogalla, B., Kahaly, M., Mayr, D., Schmoeckel, E., Niesler, B., Hester, A., Zeder-Göß, C., Kolben, T., Burges, A., Mahner, S., Jeschke, U., & Trillsch, F. (2019). Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. Cancer management and research, 117673-7684. https://doi.org/10.2147/CMAR.S210004
Czogalla, Bastian, et al. "Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology." Cancer management and research vol. 11 (2019): 7673-7684. doi: https://doi.org/10.2147/CMAR.S210004
Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göß C, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F. Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. Cancer Manag Res. 2019 Aug 14;11:7673-7684. doi: 10.2147/CMAR.S210004. eCollection 2019. PMID: 31616183; PMCID: PMC6699153.
Copy Download .nbib Format: NLM
High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients.

Cancers

Trebo A, Ditsch N, Kuhn C, Heidegger HH, Zeder-Goess C, Kolben T, Czogalla B, Schmoeckel E, Mahner S, Jeschke U, Hester A.
PMID: 32290551
Cancers (Basel). 2020 Apr 12;12(4). doi: 10.3390/cancers12040953.

Galectins are commonly overexpressed in cancer cells and their expression pattern is often associated with the aggressiveness and metastatic phenotype of the tumor. This study investigates the prognostic influence of the expression of galectin7 (Gal-7) and galectin8 (Gal-8) in...

Cite
Trebo A, Ditsch N, Kuhn C, et al. High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. Cancers (Basel). 2020;12(4)doi: 10.3390/cancers12040953.
Trebo, A., Ditsch, N., Kuhn, C., Heidegger, H. H., Zeder-Goess, C., Kolben, T., Czogalla, B., Schmoeckel, E., Mahner, S., Jeschke, U., & Hester, A. (2020). High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. Cancers, 12(4), . https://doi.org/10.3390/cancers12040953
Trebo, Anna, et al. "High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients." Cancers vol. 12,4 (2020). doi: https://doi.org/10.3390/cancers12040953
Trebo A, Ditsch N, Kuhn C, Heidegger HH, Zeder-Goess C, Kolben T, Czogalla B, Schmoeckel E, Mahner S, Jeschke U, Hester A. High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. Cancers (Basel). 2020 Apr 12;12(4). doi: 10.3390/cancers12040953. PMID: 32290551; PMCID: PMC7226378.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries